Research Article

Cell-free supernatants of lactobacilli inhibit methicilin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus and carbapenem-resistant Klebsiella strains

Volume: 60 Number: 4 December 22, 2021
EN TR

Cell-free supernatants of lactobacilli inhibit methicilin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus and carbapenem-resistant Klebsiella strains

Abstract

Aim: Antibiotic resistance is a major health problem. Recently, probiotics are used in the field of alternative/supportive medicine. Thus, in this study, we aimed to evaluate the in vitro inhibitory effects of four different cell-free supernatants (CFSs) of lactobacilli species (L. fermentum, L. plantarum, L. acidophilus and L. rhamnosus) on clinically isolated Methicilin-resistant Staphylococcus aureus (MRSA) strains, Vancomycin-resistant Enterococcus (VRE) strains, and Carbapenem-resistant Klebsiella (CRK) strains. Materials and Methods: Lactobacillus strains were grown in de Man Rogosa Sharpe broth; after filtration, CFSs were diluted to obtain 25, 50, and 100% concentrations. Pathogen bacteria were grown in tryptic soy broth with and without CFSs in a micro-plate. The bacterial growths were measured using spectrophotometric method after four hours of incubation at 37°C. One-way ANOVA followed by Dunnett’s multiple comparisons and Kruskal-Wallis test were used for statistical analyses. Results: All tested CFSs at all concentrations were found to inhibit growth of MRSA, VRE, CRK strains; the results were found statistically significant (p<0.0001). At 50% concentrations, all CFSs were found to be most effective on MRSA growth. The CFSs of L.fermentum, L.acidophilus and L.plantarum were found to be most inhibitory at 50% concentration on VRE growth. 50% diluted CFSs of L.fermentum and L.plantarum were found to be effective on growth of CRK. All results were found statistically significant (p<0.0001). Conclusion: In our study, our results support that CFSs of lactobacilli strains inhibit growth of multi-drug resistant bacteria. Their inhibitory effects were dependent on microorganisms and CFS concentrations.

Keywords

References

  1. Wright GD & Sutherland AD. New strategies for combating multidrug-resistant bacteria. Trends Mol Med 2007; 13 (6): 260-7.
  2. Van Duin D & Paterson DL. Multidrug-resistant bacteria in the community: trends and lessons learned. Infect Dis Clin 2016; 30 (2): 377-90.
  3. Falagas ME & Bliziotis IA. Pandrug-resistant Gram-negative bacteria: the dawn of the post-antibiotic era? Inter J Antimicrobial Agent 2007;29(6): 630-6.
  4. Ah YM, Kim AJ & Lee JY. Colistin resistance in Klebsiella pneumoniae. Inter J Antimicrobial Agent 2014; 44 (1): 8-15.
  5. Cattoir V & Leclercq R. Twenty-five years of shared life with vancomycin-resistant enterococci: is it time to divorce? J Antimicro Chemother 2013; 68 (4): 731-42.
  6. Voss A, Milatovic D, Wallrauch-Schwarz C, Rosdahl VT & Braveny I. Methicillin-resistant Staphylococcus aureus in Europe. Euro J Clin Microbiol Infect Dis 1994; 13 (1): 50-5.
  7. Brunel AS & Guery B. Multidrug resistant (or antimicrobial-resistant) pathogens-alternatives to new antibiotics? Swiss Med Weekly 2017; 147.
  8. Oelschlaeger TA. Mechanisms of probiotic actions—a review. Int J Med Microbiol 2010; 300: 57–62.

Details

Primary Language

English

Subjects

Health Care Administration

Journal Section

Research Article

Publication Date

December 22, 2021

Submission Date

January 23, 2021

Acceptance Date

April 24, 2021

Published in Issue

Year 2021 Volume: 60 Number: 4

Vancouver
1.Fatma Kalaycı Yüksek, Defne Gümüş, Derya Bayırlı Turan, Yasar Nakipoğlu, Rıza Adaleti, A. Mine Küçüker. Cell-free supernatants of lactobacilli inhibit methicilin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus and carbapenem-resistant Klebsiella strains. EJM. 2021 Dec. 1;60(4):332-9. doi:10.19161/etd.1037310

Cited By

Ege Journal of Medicine enables the sharing of articles according to the Attribution-Non-Commercial-Share Alike 4.0 International (CC BY-NC-SA 4.0) license.